Abstract

Purpose—Hepatocellular Carcinoma (HCC), the most common type of primary liver cancer, has a rapidly rising incidence in the United States and a very poor overall rate of survival. This epidemic is driven by the cohort of aging baby-boomers with hepatitis C virus infection and the increasing incidence of non-alcoholic steatohepatitis (NASH) cirrhosis. Because curative options are limited, the disease course creates distressing uncertainty for patients and their families around prognosis and treatment decisions. Older adults are disproportionately affected by HCC and have more co-morbidities, adding to the complexity of the disease. This population would benefit from increased access to palliative care services, which can potentially complement the treatments throughout the disease trajectory. The purpose of this review is to use existing evidence to propose a new model of palliative care integration for HCC patients. Thus, we focus on the HCC stage and the treatment algorithm, and the ways that palliative care can offer support to this population at each stage, as well as elements that can enhance patient and family support throughout the entire disease trajectory, with an emphasis on the care of older adults with HCC.

Methods—This is a narrative review in which we identify evidence-based ways that palliative care can help adults and older adults with HCC, and their families, at each stage of HCC, and throughout the disease trajectory.
**Findings**—We propose ways to integrate HCC and palliative care based on the existing evidence in both fields. Palliative care offers support of symptom management, advance care planning, and decision making in ways that are specific to each stage of HCC. We also discuss the evidence that illustrates the palliative care needs of HCC patients that span the entire course of illness, including coping with the stigmatization of liver disease, addressing informational needs at different stages, and discussions of quality of life longitudinally. Implications: Integrating palliative care into treatment of patients with HCC has the potential to improve outcomes, although more research is needed to build this evidence base.

**Keywords**
Hepatocellular carcinoma; palliative care; cirrhosis; supportive oncology; geriatric oncology

**Introduction**
Hepatocellular carcinoma (HCC) is a dreaded complication of liver disease that has a poor rate of overall survival. Patients undergo many different types of treatments throughout the course of disease. The treatment algorithm can be complex, and patients face considerable uncertainty around treatment and prognosis. Because HCC occurs in the context of underlying liver disease, this population suffers from the symptoms of both end-stage liver disease and cancer. Hepatologists play a central role in HCC management. Multi-disciplinary HCC tumor boards are often led by hepatologists, with the involvement of many different types of specialists to address the different treatment modalities. In addition to the medical complexity of HCC, a diagnosis of HCC is emotionally overwhelming for anyone, but in particular for older adults, who may face additional treatment and symptom challenges due to chronic conditions.

Palliative care, which is specialized interdisciplinary care that focuses on quality of life while living with a serious illness, has the potential to offer additional support to patients with HCC and their families as they navigate life with the disease. However, little is known about the specific palliative care needs of these patients, and particularly older adults with multiple co-morbidities. No HCC-specific models of palliative care delivery have been described, and patients with end-stage liver disease rarely receive palliative care, even at the end of life. This narrative review will focus on the aspects of HCC that make it a uniquely complex and distressing illness, and the ways that existing evidence suggests that palliative care can provide support throughout the course of HCC. Specifically, we will review the course of HCC by stage and propose specific, ways that palliative care can be helpful at each stage of HCC, as well as longitudinally throughout the disease course. We will then discuss some of the challenges of integrating palliative care into the HCC treatment landscape, and propose future research directions to address this gap in the healthcare literature.

**HCC is a complex disease with an uncertain course**
HCC is the most common type of primary liver cancer and the second leading cause of cancer-related mortality worldwide. In the United States (US) approximately 30,000 adults...
are diagnosed with HCC each year and 21,000 die. The incidence is rising in the setting of a hepatitis C virus epidemic. Of note, relatively new, highly effective anti-viral hepatitis C treatments are available, but their effect on the rising incidence of HCC is not yet known. The proportion of patients on the liver transplant waiting list for malignancy tripled between 2005 and 2015. In addition, an increasing proportion of those affected by HCC have non-alcoholic steatohepatitis (NASH), which is associated with the obesity epidemic and metabolic syndrome.

HCC affects older adults with chronic liver disease. The risk of developing HCC rises with age, with more than 15-fold increase after 65 years of age among hepatitis C-infected patients. The average age of HCC patients awaiting liver transplant has risen in recent years, from 51.2 to 55.7 years, and the proportion of those waiting who are older than 60 years has more than doubled from 19% to 42%.

HCC develops in the context of chronic liver inflammation or infection, and in most cases, underlying cirrhosis. Thus, because of concurrent liver disease, this cancer has an unpredictable disease course, and the treatment algorithm is uniquely and increasingly complex, with many potential new treatments on the horizon. Treatment modalities include surgical resection, liver transplant, interventional radiology procedures (embolization), chemotherapy, and immunotherapy, in addition to the management of the underlying chronic liver disease. Older adults often face multi-morbidity requiring many medical visits, thus the uniquely complex treatment scheme of HCC for this population is potentially quite burdensome, when added on top of the numerous other visits needed to treat their other medical illnesses. Furthermore, the presence of symptoms of underlying liver disease, like minimal hepatic encephalopathy, can lead to further deterioration of patients’ functional status.

A major source of uncertainty within the HCC treatment algorithm is transplant: candidacy is not certain and may change over time with disease progression. HCC may progress, or become more widespread, while patients are on the liver transplant waiting list, thus precluding transplantation. Secondly, in the U.S. the United Network for Organ Sharing (UNOS) policies governing HCC patient placement on the liver transplant waiting list have recently become more stringent. Patients are listed according to their Model for End-Stage Liver Disease (MELD) score, which is calculated from serum bilirubin, prothrombin time, and renal function and ranges from six (less ill, lower waitlist priority) to greater than 40 (gravely ill, higher waitlist priority). HCC patients receive additional points based on time spent on the waiting list. However, HCC patients now have a waiting period before listing and a MELD score cap, and their effects on waiting times and waitlist mortality for HCC patients are not yet known.

Early palliative care would benefit HCC patients

Early and consistent access to palliative care would benefit HCC patients and their families. Palliative care is interdisciplinary care provided to people with a serious illness, and can be offered at any stage of disease and at any age. Palliative care can be delivered concurrently with curative or disease-modifying treatments. The focus of palliative care is on quality of
life, through the management of symptoms, discussion of treatment preferences, provision of psychosocial support, including religion and spirituality, and coordination of care. Palliative care has been shown to reduce patient and family suffering, reduce healthcare utilization, and even improve survival in the context of cancer. The American Society of Clinical Oncology now recommends routine inclusion of palliative care in the care of people with cancer.

The landmark study in 2010 by Temel and colleagues showed that an ambulatory early palliative care intervention for advanced lung cancer patients improved quality of life and symptom control. They also found that the intervention group had longer survival while receiving less aggressive end-of-life care. The content of the visits was tailored to the stage of the patients’ disease, with earlier visits focused on building rapport and providing support; discussions around end-of-life care preferences occurred when patients became sicker. A qualitative study of palliative care practitioners revealed that the clinical approach to providing early palliative care for cancer patients has three major themes: (1) symptom management, (2) facilitation of coping, accepting, and planning, and (3) helping to improve medical understanding by the patient.

Table 1 features four domains of palliative care that are relevant to the care of people with HCC, adapted from the clinical guidelines published by the National Consensus Project for Quality Palliative Care. Palliative care practitioners can help manage symptoms in a way that complements management of specialists, including hepatologists, oncologists, or surgical oncologists. The symptoms associated with HCC that are listed in the right column reflect the findings of Hansen et al., Sun and Sarna, and Kaiser et al. Pain management is an area where palliative care can complement the management of HCC specialists because of the complexity of dosing analgesics for patients with hepatic impairment (most HCC patients), prevalent history of substance use among patients with chronic liver disease, and the opioid addiction epidemic in the U.S. Since most HCC patients also have cirrhosis, they also have symptoms that reflect their underlying liver dysfunction. Notably hepatic encephalopathy can be very distressing symptom for family members. In addition to the difficulties with metabolism of medications caused by liver disease, older adults may be more susceptible to side effects of medications including delirium related to medications, gait imbalance, urinary retention, and falls.

Advance care planning (table 1) refers to patient preferences about how they receive care and who might make decisions for them if they are unable. Physician (or Medical) Orders for Life-Sustaining Treatment (POLST or MOLST; differs by U.S. State) is available throughout the U.S. and specifies preferences related to care received—e.g., resuscitation, ventilation, artificial nutrition and hydration, hospitalization, and renal replacement therapy. Psychosocial support (table 1) might include referral for religious or faith-based resources, child-life or art therapy, or referral to support groups. Finally, care coordination (table 1) might include functional assessment, identification of needed home based care, and screening for geriatric syndromes, like frailty, fall risk, and polypharmacy.

In addition, inpatient palliative care consultation for advanced cancer patients is associated with reduced cost. Morrison and colleagues have shown that early inpatient palliative care
reduced cost, and that earlier consultation resulted in larger cost savings.\textsuperscript{31} They also demonstrated that reduced length of hospital stay had the largest impact on the observed cost reduction.\textsuperscript{43} It is important to note that the same group has reported improved patient and family satisfaction by surveying bereaved family members,\textsuperscript{29} thus demonstrating that palliative care consultation may reduce cost while also improving patient and family satisfaction.

Reduced healthcare utilization associated with palliative care consultation for people with cirrhosis has been reported by Patel\textit{ et al}. in their study of palliative care receipt among Medicare beneficiaries with cirrhosis. Specifically, they showed that palliative care consultation was associated with fewer numbers of procedures at the end of life.\textsuperscript{12} The existing evidence for the impact of palliative care on cost focuses on advanced disease (cancer or cirrhosis); little is known about the potential impact of palliative care on the intensity and cost of care received by HCC patients with early stage disease.

The principles of palliative care are especially pertinent to older adults with HCC, who have increased numbers of co-morbid conditions, thus complicating treatment decisions. Hewitt and colleagues reported that cancer survivors with chronic diseases were more likely to report limitations of activities of daily living (e.g., bathing, dressing) or instrumental activities of daily living (e.g., shopping for groceries, managing money) and being unable to work because of a health condition.\textsuperscript{44} Among cancer survivors with comorbid chronic conditions the likelihood of poor health and disability was much higher. Four out of five older adults have at least one chronic condition,\textsuperscript{24} and multiple chronic conditions are associated with poor functional status and quality of life, and adverse drug events.\textsuperscript{45} Among older women with breast cancer for instance, level of symptom burden and number of co-morbidities are strongly associated with physical function.\textsuperscript{46} Significant chronic conditions may also compromise treatment effectiveness and treatment adherence.\textsuperscript{47} In addition to HCC related symptoms, older adults may have a more complicated symptom presentation because of more co-morbid conditions, adding additional complexity and challenges to an already complex treatment algorithm and symptom profile. Palliative care delivery to older adults with HCC may have an even greater cost saving effect as compared with younger people: Morrison and colleagues found in their analysis impact of palliative care consultation for cancer patients, that cost savings are increased for patients with increased numbers of co-morbidities.\textsuperscript{48}

Potential early palliative care interventions, tailored to the needs of people with HCC and their families, should span the course of illness. The role of palliative/supportive care in the care of HCC patients has been suggested previously.\textsuperscript{49} Many of the services that palliative care can provide, including symptom management, decisional support, care coordination, and psychosocial support are needed in the early stages of HCC, when curative treatments are still available. However little has been written about the best ways to integrate these services into existing models of HCC care.

Palliative care delivery to HCC patients may ideally be connected to the multi-disciplinary tumor board, as previously described.\textsuperscript{50–53} There is observational evidence that patients managed through a multi-disciplinary tumor board have higher rates of therapy and longer
And while improvement of quality-of-life for HCC patients is an important stated objective of the multidisciplinary approach to HCC care, there is a paucity of literature on measured outcomes in this area, and the models do not include palliative care, or a focus on older patients with HCC. HCC is amenable to early palliative care intervention, and the disease-specific triggers and content of the visits need to be tailored to the specific needs of HCC patients and their families.

**Palliative care can be helpful to HCC patients in different ways at each stage**

Palliative care presents an opportunity to address illness understanding and information sharing at all stages. Palliative care clinicians are uniquely suited to help patients navigate the process of treatment decisions while considering how to best define and maintain quality of life while living with a serious illness like HCC. Here we describe potential roles of palliative care at each Barcelona Clinic Liver Cancer (BCLC) stage. The BCLC staging system is endorsed by major clinical practice guidelines. It is divided into five stages: stage 0, A (early), B (intermediate), C (advanced), and D (terminal). The staging system forms the basis for the HCC treatment algorithm and prognostication. Table 2 outlines a framework to approach the development of palliative care that is tailored to the trajectory of HCC. The first row describes an overview of the clinical features that characterize each stage. Below that, we have listed ways in which palliative care might enhance the care of HCC patients at each stage. The bottom row shows ways in which palliative care can help these patients throughout the course of illness that are specific to HCC.

**Barcelona Clinic Liver Cancer (BCLC) stage 0 and A HCC**

Patients with very early stage HCC (BCLC stage 0) have a single liver nodule less than 2 cm, while patients with early stage HCC (BCLC stage A) have a single nodule less than 5 cm or three or fewer nodules less than 3 cm. They are eligible for consideration of curative treatments, including ablation, resection, or liver transplant. Transplant candidacy is determined primarily by the Milan Criteria: a single tumor less than 5 cm in diameter, or up to three tumors not larger than 3 cm in diameter, confined to the liver. Median survival for this cohort is more than 5 years with treatment.

Some of the core principles of palliative care can be helpful in supporting patients and families in decision making. Thus, it stands to reason that there are opportunities to address decision making around surgical intervention for early stage HCC patients. As outlined by Mosenthal and colleagues in their recent publication in the *Annals of Surgery*, there are no studies to date that test a surgical palliative care intervention during the perioperative period. Advance care planning before surgical intervention is particularly important for patients who face greater risk of complication, like older adults or patients with significant co-morbidities. Patients with early stage HCC may benefit from discussions about treatment preferences early. Ideally they would have such discussions with a provider (physician, nurse practitioner, or social worker trained in communication techniques) whose skill in communication complements the expertise of the HCC-treating physicians. Patients with BCLC stage A HCC who are listed for liver transplant risk disease progression, making
them ineligible for transplant, and may represent a group of patients with potential unmet palliative care needs. Mehta et al. report, in their three-center cohort study of HCC patients listed for liver transplant, a waitlist dropout rate of 18.4% with a median time to dropout of 11.3 months. Similarly, Salvalaggio et al. report single center retrospective data that demonstrates a one-year dropout rate of 17.7%. Importantly, they found that patients who dropped out before receiving a transplant did so either because of the severity of their underlying liver disease, or were less likely to respond to embolization therapy and had higher alpha fetoprotein values, suggesting more aggressive disease. These data suggest that the event of waitlist removal may mean patients have a greater need for palliative care, both for their disease severity and resulting symptom burden, and for support during a time of uncertainty and distress over their inability to receive curative therapies. Removal from the transplant waiting list may therefore be an important point in the HCC trajectory for treating physicians to refer their patients to palliative care as an added layer of support. This may also serve as a strategy for triaging patients to palliative care where availability of specialty-level palliative care is more limited, given palliative care staffing shortages.

In addition, within this early-stage group, older adults are particularly vulnerable to prognostic uncertainty. It may be more difficult, or even impossible to undergo surgery or be listed on the liver transplant waiting list and receive a transplant. Older recipient age is associated with higher mortality after liver transplant, as compared with younger recipients. A meta-analysis of HCC treatment for older adults (70 years or more) by Hung and Guy showed similar survival for older adults who underwent resection, as compared with younger individuals, but lower survival for those who underwent ablation.

BCLC stage B HCC

Patients with intermediate stage HCC (BCLC stage B) have multinodular HCC, or tumors outside of Milan Criteria, good functional status, and compensated liver disease. They may receive local anti-neoplastic treatments, including trans-arterial chemo-embolization (TACE) and 90Y-radioembolization. Though they are not eligible for transplantation, their treatment may result in downstaging of their tumors and potential liver transplant candidacy. People with intermediate stage HCC have a median overall survival of 26 months.

The treatment of intermediate stage HCC is notable for the multiple specialists that may be involved in the patients’ treatment plan. Intermediate stage patients may be following with, and receiving information from, multiple specialists at this stage: interventional radiology, medical oncology, transplant hepatology, and surgical oncology. Furthermore, for this group, care coordination may be particularly important in addition to decisional, informational, and symptomatic support. Palliative care teams are uniquely skilled in care coordination and could provide support to patients and families as they navigate the different treatment modalities for intermediate stage disease.

BCLC stage C HCC

Patients with advanced HCC (BCLC stage C) have portal invasion, lymph node involvement, metastases, and/or reduced functional status, but compensated liver disease as defined by
Child Pugh A and B, a scoring system that rates severity of liver disease based on presence of underlying symptoms. Chemotherapy has been the mainstay of treatment for patients with advanced HCC for the last ten years. Until recently, no other approved therapies were approved beyond sorafenib (a tyrosine kinase inhibitor), so those who were not able to tolerate or did not benefit had only clinical trials or supportive care as therapeutic options. Within the last year, there have been two major developments in the treatment of advanced HCC. Regorafenib has been approved by the Federal Food and Drug Administration as second line therapy for HCC. Lenvatinib has been submitted to the FDA for approval, as first-line therapy for advanced HCC, given its noninferiority to sorafenib (with respect to overall survival). Both of these medications are kinase inhibitors. These new developments will offer additional treatment options for this group, and will add complexity to their decisions about treatments. Median survival for BCLC C patients is 11 months with treatment.

BCLC stage C HCC

Palliative care can help this group with both symptomatic management and decisional support. In their longitudinal qualitative study of the experience of HCC patients near the end of life, Hansen et al found that more than half of the participants considered stopping cancer treatment at some point during the study. They found that a common theme in this decision making process was a wish to maintain their quality of life, yet their perception of a good quality of life understandably changed with the progression of their disease. Exploration of how a patient defines good quality of life is an important way that palliative care may provide additional support to patients at this advanced stage, as they undergo treatment, and possible disease progression and worsening symptom burden.

Patients with BCLC stage D HCC (often referred to as terminal stage) have impaired liver function (Child Pugh C) and reduced functional status. Lin et al report that HCC patients with Child Pugh C cirrhosis had higher rates of peripheral edema, ascites, dyspnea, jaundice, thrombocytopenia, and hepatic encephalopathy as compared with Child Pugh A and B patients. Disease-directed treatments are not available for patients with terminal HCC, and their median survival is less than three months. Patients with BCLC stage D HCC can be offered supportive care. Palliative care practitioners can help at this stage with treatment of complex symptoms associated with worsening disease and coping with the lifestyle changes that come with patients’ progressive disability. Knowledge and support in the provision of end-of-life care may be lacking for HCC patients and families.

Hospice is an important consideration for patients with terminal stage HCC, and palliative care specialists can help with discussion of patient preferences for hospice referral. Hospice is interdisciplinary care that is distinguished from palliative care (which can be delivered at all stages of illness), because it is for people who (1) are close to the end of their lives, generally with a less than six-month prognosis, and (2) are no longer receiving treatments with curative intent. Hospice use is associated with improved quality of care at the end of life.

Like palliative care consultation for advance cancer patients, hospice care at the end of life is associated with reduced healthcare utilization with improved patient satisfaction, and is
therefore an opportunity for reduced costs with care that is aligned with patient preference. Kleinpell et al. report that hospice admission during the last six months of life is associated with improved patient satisfaction ratings, better pain control, reduction in hospital days and hospital deaths, and is inversely related with hospital and intensive care unit mortality at the hospital level. For HCC patients specifically, the hospice enrollment rate for Medicare beneficiaries near the end of life is 63%. Hwang et al. reported that in Taiwan hospice care for older adults with terminal HCC was associated with improved delivery of symptomatic medications, and was associated with reduced costs. Similarly, a recent publication by Fukui et al. demonstrates lower hospitalization costs for Medicare beneficiaries with liver cancer who received hospice care. 

**Palliative care can be helpful to HCC patients longitudinally, regardless of stage**

In order to meet the needs of HCC patients throughout their illness, palliative care should be offered early, and continue longitudinally, and be tailored to the specific needs of patients with a given illness. Designing care delivery models specifically based on disease stage will not meet the needs of all patients, as there is likely to be variation among palliative care needs, particularly among older adults with other chronic conditions. Furthermore, there are specific challenges that span the course of illness that palliative care may help address (bottom-most row of table 2), which are described here.

First, HCC patients’ definition of quality of life, and their perceptions of how it is affected by their treatments, change over the course of time with disease progression. Thus, longitudinal involvement of palliative care in the care of these patients will be helpful by providing uniquely skilled practitioners to help define and monitor quality of life over time. Their interaction with palliative care may involve complex symptom management, discussion of treatment preferences, or provision of additional resources to help them cope with their illness, regardless of disease stage.

Second, the stigma around liver disease is an added burden for this population. HCC patients and their family caregivers experience stigma associated with liver disease, and may experience guilt or feel ostracized. HCC almost always arises in the setting of chronic liver disease, and in the US, common causes of chronic liver disease and/or cirrhosis that lead to HCC are viral hepatitis and obesity. In many cases the disease is a direct result of stigmatized behavior or personal characteristic: intranasal or intravenous drug use, sexual intercourse, alcohol use, and obesity. Hansen and colleagues report the experience of one participant who had experienced both breast and liver cancer compared the experiences: she noted that HCC is not one of the “good” cancers, compared leukemia or breast cancer (both cited by the participant with regard to public perception). A recent survey of caregivers for HCC patients, by Bristol-Meyers Squibb, confirms this feeling of isolation and shame: many respondents noted that stigmatization and lack of public awareness make it difficult for HCC patients to find support.

A third potentially unmet need among HCC patients that is amenable to longitudinal palliative care involvement is patient and family caregiver need for more information about...
this disease and its course. End-stage liver disease is frequently characterized by unpredictable disease exacerbations, and the treatment algorithm for HCC is complex. In their study of HCC patients’ family caregiver experience, Hansen and colleagues found a desire for more information, both in terms of treatment options, and interpreting the significance of symptoms with respect to disease progression. Similarly, the Bristol-Meyers Squibb survey of family caregivers (of HCC patients at both early and late stages) revealed that more than half of respondents felt the need for more information about the disease and its treatments, and 80% did not know where to find additional information.

**Challenges in developing HCC-specific palliative care models**

Two important factors may play a part in the barriers to integrating palliative care with the medical care of HCC patients: (1) lack of available resources and trained staff and (2) stigmatization of palliative care, particularly in the setting of liver transplant.

First, palliative care is a relatively new field and necessary resources may not be readily available for incorporation into current practice models. A recent report of palliative care growth in the US demonstrated that access to palliative care across health systems remains uneven. Factors that impact availability of hospital-based palliative care include hospital size, tax status, and geographic location. Furthermore, given the rapid growth of the field of palliative care in recent years, there is a relative shortage of specialists offering palliative care in the US. Workforce training in the principles of palliative care for both palliative care and HCC specialists is necessary to address the needs of people facing HCC.

Second, misperceptions that equate palliative care with end-of-life care may impact when and how often HCC patients are referred to palliative care as a complement to disease-directed therapy. A 2014 survey of medical oncologists revealed a belief among some respondents that palliative care is not compatible with cancer-directed treatment. Beck et al. performed a survey of liver transplant providers including nurses, physician trainees, and attending physicians at an academic transplant program. Respondents reported that palliative care services benefit patients, even when listed for liver transplant. Nonetheless, solid organ transplantation is sometimes viewed as incongruous with palliative care, usually based on the assumption that palliative care focuses on the provision of end-of-life care, on the part of both physicians and patients/families. Concurrent palliative care and transplant referral has been studied by Navarro and colleagues: they found that end-stage liver disease patients who received palliative care referrals concurrently with liver transplant evaluation had improved symptom control, and notably fewer depressive symptoms.

**Recommendations for Future Directions**

Given the complexity of HCC care and the lack of research to test the efficacy of models of palliative care delivery in this population, and particularly in older adults with HCC, more research is needed. Palliative care models that incorporate care for patients with all stages of HCC should be tested. It is important to consider measurement tools to be used in a trial of palliative care and quality-of-life focused interventions for this population. There are two HCC-specific quality-of-life questionnaires that have been validated: the European...
Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) HCC18,\textsuperscript{91} and the Functional Assessment of Cancer Therapy—Hepatobiliary (FACT-Hep) Questionnaire.\textsuperscript{92} In addition, qualitative methods should be incorporated into the design of trials that test palliative care interventions for HCC patients. This will allow incorporation of patient and family caregiver voice in real time, as the trial is carried out. Thus, the investigators can detect and respond to unanticipated or otherwise unmeasured effects of the intervention.\textsuperscript{93} This will help to inform future studies and create more effective models of HCC care.

There are different types of palliative care interventions that have been tested in cancer patients. Most notably, inpatient palliative care consultation and early/ambulatory palliative care interventions have been shown to improve quality and in some cases quantity of life, and reduce rates of healthcare utilization. Because we believe that continuity of palliative care that dovetails with HCC-specific management, we propose that study of early, outpatient-based palliative care interventions will be central to successful delivery of palliative care for HCC patients. Furthermore, there is evidence that longitudinal palliative care delivery has different patterns of maximal benefit based on the type of primary cancer. Temel and colleagues showed in their 2017 randomized controlled trial of palliative care for patients with lung and gastrointestinal (GI) cancers\textsuperscript{94} that patients with lung cancer had significant improvement in quality of life and depressive symptoms at the 12-week time-point. In contrast, those with GI cancers who received palliative care did not show significant improvement over usual care until the 24-week time-point. In order to understand the timing and ways that HCC patients will benefit from palliative care, research should focus on implementation across the spectrum of HCC care.

Enhanced information sharing may benefit this population, so HCC-specific palliative care interventions should include components of information sharing and disease understanding. Prior studies have shown that patients and family caregivers perceive a lack of information about the disease.\textsuperscript{3, 41} The unpredictable disease course of HCC is similar to the end-organ failure model of disease trajectory described previously, most extensively in the context of heart failure.\textsuperscript{95} These patients often face a course that may be punctuated by disease exacerbations, any one of which could result in death. Furthermore, regardless of whether patients have end-organ failure or cancer, the pattern of disability during the last year of life is uncertain.\textsuperscript{96} As recommended for heart failure patients,\textsuperscript{97} regularly scheduled visits with their provider that are woven into the HCC treatment algorithm could potentially be helpful in making sure patients and families have a mechanism to receive information and review the disease course and milestones, or when there is an acute need, for instance when the patient is hospitalized unexpectedly. This could help address the lack of information felt by caregivers in previous studies.\textsuperscript{41, 84}

Finally, the existing multi-disciplinary model of care for pre- and post-transplant patients is likely more amenable to an embedded palliative care model, rather than a consultative model, such that the palliative care team members are well known to the multi-disciplinary team and regularly care for the patients seen in the liver cancer practice. This model will help build trust and facilitate close communication between providers, while helping HCC patients and families navigate the complex course of this disease.
Conclusion

Patients and their families face unique challenges from HCC, a complex, deadly, and increasingly common disease. As demonstrated in palliative care research for other serious diagnoses, palliative care may offer an added layer of support to the multidisciplinary approach to HCC care, especially in the specific areas of symptom management, psychosocial coping, decisional support, and disease understanding. We propose that integrating palliative care into the multidisciplinary approach to care may be most feasible and effective model. This integration may be accomplished through both provision of specialty level palliative care, particularly at specific points in the disease course, and by incorporating specific elements of palliative care into routine HCC care. Research in this area should focus on testing interventions throughout the course of HCC, with outcomes that include quality of life measures and design that incorporates patient and family voice. HCC is a complex disease, and even more so for older adults with multiple co-morbidities. Thus, we need to better understand the specific needs of HCC patients so that their palliative care needs can be met throughout the disease course. We believe that enhancement of palliative care services that complement the HCC treatment algorithm will significantly improve the care of HCC patients and their families.

Acknowledgments

The authors would like to thank Suzy L. Goldhirsch for her help in preparing this manuscript.

Funding sources

This work was supported by The National Palliative Care Research Center and by the Claude D. Pepper Older Americans Independence Center at the Icahn School of Medicine (National Institute on Aging, 5 P30 AG028741 08).

Abbreviations

| Abbreviation | Description                      |
|--------------|----------------------------------|
| HCC          | Hepatocellular carcinoma         |
| NASH         | Non-alcoholic steatohepatitis    |
| US           | United States                    |
| MELD         | Model for end-stage liver disease|
| BCLC         | Barcelona Clinic Liver Cancer    |
| UNOS         | United Network for Organ Sharing |
| MOLST/POLST  | Medical/Physician Orders for Life-Sustaining Treatments |
| TACE         | Trans-arterial chemo-embolization|
| EORTC QLQ    | European Organization for Research and Treatment of Cancer Quality of Life Questionnaire |
| FACT-Hep     | Functional Assessment of Cancer Therapy—Hepatobiliary |
References

1. Jemal A, Ward EM, Johnson CJ, et al. Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival. J Natl Cancer Inst. 2017;109.

2. Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016; 2:16018. [PubMed: 27158749]

3. Hansen L, Rosenkranz SJ, Vaccaro GM, Chang MF. Patients With Hepatocellular Carcinoma Near the End of Life: A Longitudinal Qualitative Study of Their Illness Experiences. Cancer Nurs. 2015; 38:E19–27.

4. Sun VC, Sarna L. Symptom management in hepatocellular carcinoma. Clin J Oncol Nurs. 2008; 12:759–66. [PubMed: 18842532]

5. Hansen L, Dieckmann NF, Kolbeck KJ, Naugler WE, Chang MF. Symptom Distress in Patients With Hepatocellular Carcinoma Toward the End of Life. Oncol Nurs Forum. 2017; 44:665–73. [PubMed: 29052660]

6. Serper M, Taddei TH, Mehta R, et al. Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality. Gastroenterology. 2017; 152:1954–64. [PubMed: 28283421]

7. Heather E, Whitson CMB. Managing Multiple Comorbidities. UpToDate. 2017

8. Kelley AS, Morrison RS. Palliative Care for the Seriously Ill. N Engl J Med. 2015; 373:747–55. [PubMed: 26287850]

9. Woodrell CD, Schiano TD, Goldstein NE. Hepatocellular Carcinoma: A Wrinkle in the Emerging Palliative Care/Oncology Paradigm. J Oncol Pract. 2017; 13:404–5. [PubMed: 28504903]

10. Poonja Z, Brisebois A, van Zanten SV, Tandon P, Meeberg G, Karvellas CJ. Patients with cirrhosis and denied liver transplants rarely receive adequate palliative care or appropriate management. Clin Gastroenterol Hepatol. 2014; 12:692–8. [PubMed: 23978345]

11. Kathpalia P, Smith A, Lai JC. Underutilization of palliative care services in the liver transplant population. World J Transplant. 2016; 6:594–8. [PubMed: 27683638]

12. Patel AA, Walling AM, Ricks-Oddie J, May FP, Saab S, Wenger N. Palliative Care and Health Care Utilization for Patients With End-Stage Liver Disease at the End of Life. Clin Gastroenterol Hepatol. 2017; 15:1612–9. e4. [PubMed: 28179192]

13. Cancer Facts and Figures 2017. Atlanta: American Cancer Society; 2017.

14. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014; 74:2913–21. [PubMed: 24840647]

15. El-Serag HB. Hepatocellular carcinoma. The New England journal of medicine. 2011; 365:1118–27. [PubMed: 21992124]

16. Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013; (47 Suppl):S2–6. [PubMed: 23632345]

17. White DL, Thrift AP, Kanwal F, Davila J, El-Serag HB. Incidence of Hepatocellular Carcinoma in all 50 United States, From 2000 Through 2012. Gastroenterology. 2016

18. Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2015 Annual Data Report: Liver. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2017; 17(Suppl 1):174–251.

19. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015; 148:547–55. [PubMed: 25461851]

20. Asahina Y, Tsuchiya K, Tamaki N, et al. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology. 2010; 52:518–27. [PubMed: 20683951]

21. Su F, Yu L, Berry K, et al. Aging of Liver Transplant Registrants and Recipients: Trends and Impact on Waitlist Outcomes, Post-Transplantation Outcomes, and Transplant-Related Survival Benefit. Gastroenterology. 2016; 150:441–53. e6. [PubMed: 26522262]

22. Sia D, Llovet JM. Liver cancer: Translating ‘omics’ results into precision medicine for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2017; 14:571–2. [PubMed: 28765583]
23. Harding JJ, El Dika I, Abou-Alfa GK. Immunotherapy in hepatocellular carcinoma: Primed to make a difference? Cancer. 2016; 122:367–77. [PubMed: 26540029]

24. [Accessed January 6, 2018] Chronic Care: A Call to Action for Health Reform, Chapter 1: Chronic Conditions Among Older Americans. at https://assets.aarp.org/rgcenter/health/beyond_50_hcr.pdf

25. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001; 33:464–70. [PubMed: 11172350]

26. Bakitas M, Lyons KD, Hegel MT, et al. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. Jama. 2009; 302:741–9. [PubMed: 19690306]

27. Temel JS, Greer JA, El-Jawahri A, et al. Effects of Early Integrated Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical Trial. J Clin Oncol. 2016;JCO2016705046.

28. Teno JM, Clarridge BR, Casey V, et al. Family perspectives on end-of-life care at the last place of care. Jama. 2004; 291:88–93. [PubMed: 14709580]

29. Gelfman LP, Meier DE, Morrison RS. Does palliative care improve quality? A survey of bereaved family members. J Pain Symptom Manage. 2008; 36:22–8. [PubMed: 18411019]

30. May P, Normand C, Morrison RS. Economic impact of hospital inpatient palliative care consultation: review of current evidence and directions for future research. Journal of palliative medicine. 2014; 17:1054–63. [PubMed: 24984168]

31. May P, Garrido MM, Cassel JB, et al. Prospective Cohort Study of Hospital Palliative Care Teams for Inpatients With Advanced Cancer: Earlier Consultation Is Associated With Larger Cost-Saving Effect. J Clin Oncol. 2015; 33:2745–52. [PubMed: 26056178]

32. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. The New England journal of medicine. 2010; 363:733–42. [PubMed: 20818875]

33. Bakitas MA, Tosteson TD, Li Z, et al. Early Versus Delayed Initiation of Concurrent Palliative Oncology Care: Patient Outcomes in the ENABLE III Randomized Controlled Trial. J Clin Oncol. 2015; 33:1438–45. [PubMed: 25800768]

34. Ferrell BR, Temel JS, Temin S, et al. Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017; 35:96–112. [PubMed: 28034065]

35. Yoong J, Park ER, Greer JA, et al. Early palliative care in advanced lung cancer: a qualitative study. JAMA Intern Med. 2013; 173:283–90. [PubMed: 23358690]

36. Back AL, Park ER, Greer JA, et al. Clinician roles in early integrated palliative care for patients with advanced cancer: a qualitative study. J Palliat Med. 2014; 17:1244–8. [PubMed: 25390467]

37. [Accessed July 31, 2017] Clinical Practice Guidelines for Quality Palliative Care. Thirdat http://keyweb24.com/nchpc/wp-content/uploads/2017/04/NCP_Clinical_Practice_Guidelines_3rd_Edition.pdf

38. Kaiser K, Mallick R, Butt Z, Mulcahy MF, Benson AB, Cella D. Important and relevant symptoms including pain concerns in hepatocellular carcinoma (HCC): a patient interview study. Support Care Cancer. 2014; 22:919–26. [PubMed: 24258355]

39. Koch M, Banys P. Liver transplantation and opioid dependence. JAMA. 2001; 285:1056–8. [PubMed: 11209177]

40. Dart RC, Surratt HL, Cicero TJ, et al. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med. 2015; 372:241–8. [PubMed: 25587948]

41. Hansen L, Rosenkranz SJ, Wherity K, Sasaki A. Living With Hepatocellular Carcinoma Near the End of Life: Family Caregivers’ Perspectives. Oncol Nurs Forum. 2017; 44:562–70. [PubMed: 28820518]

42. Hickman SE, Keevern E, Hammes BJ. Use of the physician orders for life-sustaining treatment program in the clinical setting: a systematic review of the literature. J Am Geriatr Soc. 2015; 63:341–50. [PubMed: 25644280]

43. May P, Garrido MM, Cassel JB, et al. Cost analysis of a prospective multi-site cohort study of palliative care consultation teams for adults with advanced cancer: Where do cost-savings come from? Palliat Med. 2017; 31:378–86. [PubMed: 28156192]

Clin Ther. Author manuscript; available in PMC 2019 April 01.
44. Hewitt M, Rowland JH, Yancik R. Cancer survivors in the United States: age, health, and disability. J Gerontol A Biol Sci Med Sci. 2003; 58:82–91. [PubMed: 12560417]
45. Salive ME. Multimorbidity in older adults. Epidemiol Rev. 2013; 35:75–83. [PubMed: 23372025]
46. Bellury L, Pett MA, Ellington L, Beck SL, Clark JC, Stein KD. The effect of aging and cancer on the symptom experience and physical function of elderly breast cancer survivors. Cancer. 2012; 118:6171–8. [PubMed: 22674036]
47. Sogaard M, Thomsen RW, Bossen KS, Sorensen HT, Norgaard M. The impact of comorbidity on cancer survival: a review. Clin Epidemiol. 2013; 5:3–29. [PubMed: 24227920]
48. May P, Garrido MM, Cassel JB, et al. Palliative Care Teams’ Cost-Saving Effect Is Larger For Cancer Patients With Higher Numbers Of Comorbidities. Health Aff (Millwood). 2016; 35:44–53. [PubMed: 26733700]
49. Kumar M, Panda D. Role of supportive care for terminal stage hepatocellular carcinoma. J Clin Exp Hepatol. 2014; 4:S130–9. [PubMed: 25755605]
50. Naugler WE, Alsina AE, Frenette CT, Rossaro L, Sellers MT. Building the multidisciplinary team for management of patients with hepatocellular carcinoma. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2015; 13:827–35. [PubMed: 24909910]
51. Schwartz ME, Sung M, Mor E, et al. A multidisciplinary approach to hepatocellular carcinoma in patients with cirrhosis. J Am Coll Surg. 1995; 180:596–603. [PubMed: 7749537]
52. Rilling WS, Drooz A. Multidisciplinary management of hepatocellular carcinoma. J Vase Interv Radiol. 2002; 13:S259–63. [PubMed: 12354844]
53. Gish RG, Lencioni R, Di Bisceglie AM, Raoul JL, Mazzaferrero V. Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2012; 6:173–85. [PubMed: 22375523]
54. Agarwal PD, Phillips P, Hillman L, et al. Multidisciplinary Management of Hepatocellular Carcinoma Improves Access to Therapy and Patient Survival. J Clin Gastroenterol. 2017; 51:845–9. [PubMed: 28877082]
55. Brunot A, Le Sourd S, Pracht M, Edeline J. Hepatocellular carcinoma in elderly patients: challenges and solutions. J Hepatocell Carcinoma. 2016; 3:9–18. [PubMed: 27574587]
56. European Association For The Study Of The Liver & European Organisation For Research And Treatment Of Cancer. EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology. 2012; 56:908–43. [PubMed: 22424438]
57. Mazzaferrero V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334:693–9. [PubMed: 8594428]
58. Evans WG, Tulsky JA, Back AL, Arnold RM. Communication at times of transitions: how to help patients cope with loss and re-define hope. Cancer J. 2006; 12:417–24. [PubMed: 17034677]
59. Lilley EJ, Cooper Z, Schwarze ML, Mosenthal AC. Palliative Care in Surgery: Defining the Research Priorities. Ann Surg. 2018; 267:66–72. [PubMed: 28471764]
60. Mehta N, Heimbach J, Lee D, et al. Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time “Sweet Spot”. Transplantation. 2017; 101:2071–8. [PubMed: 28353492]
61. Salvalaggio PR, Felga GE, Guardia BD, et al. Time of Dropout From the Liver Transplant List in Patients With Hepatocellular Carcinoma: Clinical Behavior According to Tumor Characteristics and Severity of Liver Disease. Transplant Proc. 2016; 48:2319–22. [PubMed: 27742288]
62. Lupu D. American Academy of H, Palliative Medicine Workforce Task F. Estimate of current hospice and palliative medicine physician workforce shortage. J Pain Symptom Manage. 2010; 40:899–911. [PubMed: 21145468]
63. Xing M, Kim HS. Independent prognostic factors for posttransplant survival in hepatocellular carcinoma patients undergoing liver transplantation. Cancer Med. 2017; 6:26–35. [PubMed: 27860456]
64. Hung AK, Guy J. Hepatocellular carcinoma in the elderly: Meta-analysis and systematic literature review. World J Gastroenterol. 2015; 21:12197–210. [PubMed: 26576104]
65. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002; 359:1734–9. [PubMed: 12049862]
66. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011; 140:497–507. e2. [PubMed: 21044630]
67. Yao FY, Mehta N, Flemming J, et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology (Baltimore, Md). 2015; 61:1968–77.
68. Parikh ND, Waljee AK, Singal AG. Downstaging hepatocellular carcinoma: A systematic review and pooled analysis. Liver Transpl. 2015; 21:1142–52. [PubMed: 25981135]
69. Siouta N, Van Beek K, van der Eerden ME, et al. Integrated palliative care in Europe: a qualitative systematic literature review of empirically-tested models in cancer and chronic disease. BMC Palliat Care. 2016; 15:56. [PubMed: 27391378]
70. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973; 60:646–9. [PubMed: 4541913]
71. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359:378–90. [PubMed: 18650514]
72. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 389:56–66. [PubMed: 27932229]
73. Oikonomopoulos G, Aravind P, Sarker D. Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma? Future Oncol. 2016; 12:465–76. [PubMed: 26785762]
74. Lin MH, Wu PY, Tsai ST, Lin CL, Hwang SJ. Hospice palliative care for patients with hepatocellular carcinoma in Taiwan. Palliat Med. 2004; 18:93–9. [PubMed: 15046405]
75. Cabibbo G, Maida M, Genco C, et al. Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study. World J Hepatol. 2012; 4:256–61. [PubMed: 23060970]
76. Kelley AS, Deb P, Du Q, Aldridge Carlson MD, Morrison RS. Hospice enrollment saves money for Medicare and improves care quality across a number of different lengths-of-stay. Health Aff (Millwood). 2013; 32:552–61. [PubMed: 23459735]
77. Kleinpell R, Vasilevskis EE, Fogg L, Ely EW. Exploring the association of hospice care on patient experience and outcomes of care. BMJ Support Palliat Care. 2016
78. Sanoff HK, Chang Y, Reimers M, Lund JL. Hospice Utilization and Its Effect on Acute Care Needs at the End of Life in Medicare Beneficiaries With Hepatocellular Carcinoma. J Oncol Pract. 2017; 13:e197–e206. [PubMed: 28029300]
79. Hwang SJ, Chang HT, Hwang IH, Wu CY, Yang WH, Li CP. Hospice offers more palliative care but costs less than usual care for terminal geriatric hepatocellular carcinoma patients: a nationwide study. J Palliat Med. 2013; 16:780–5. [PubMed: 23790184]
80. Fukui N, Golabi P, Ongsuren M, de Avila L, Bush H, Younossi ZM. Hospice care in Medicare patients with primary liver cancer: the impact on resource utilisation and mortality. Aliment Pharmacol Ther. 2018; 47:680–8. [PubMed: 29314093]
81. Gaertner J, Wolf J, Halleck M, Glossmann JP, Voltz R. Standardizing integration of palliative care into comprehensive cancer therapy--a disease specific approach. Support Care Cancer. 2011; 19:1037–43. [PubMed: 21432009]
82. Mahtani-Chugani V, Gonzalez-Castro I, de Ormijana-Hernandez AS, Martin-Fernandez R, de la Vega EF. How to provide care for patients suffering from terminal non-oncological diseases: barriers to a palliative care approach. Palliat Med. 2010; 24:780–8. [PubMed: 20817747]
83. Sanyal A, Poklepovic A, Mouyneur E, Barghout V. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin. 2010; 26:2183–91. [PubMed: 20666689]
84. Bristol-Meyers-Squibb. U.S. Survey of Liver Cancer Caregivers. 2017
85. Dumanovsky T, Augustin R, Rogers M, Lettang K, Meier DE, Morrison RS. The Growth of Palliative Care in U.S. Hospitals: A Status Report. J Palliat Med. 2016; 19:8–15. [PubMed: 26417923]
86. Cruz-Oliver DM, Bernacki R, Cooper Z, et al. The Cambia Sojourns Scholars Leadership Program: Conversations with Emerging Leaders in Palliative Care. J Palliat Med. 2017; 20:804–12. [PubMed: 28525294]
87. Schenker Y, Crowley-Matoka M, Dohan D, et al. Oncologist factors that influence referrals to subspecialty palliative care clinics. J Oncol Pract. 2014; 10:e37–44. [PubMed: 24301842]
88. Beck KRPS, O’Riordan DL, Peters MG. Use of Palliative Care Consultation for Patients with End-Stage Liver Disease: Survey of Liver Transplant Service Providers. Journal of palliative medicine. 2016; 19:836–41. [PubMed: 27092870]
89. Colman RE, Curtis JR, Nelson JE, et al. Barriers to optimal palliative care of lung transplant candidates. Chest. 2013; 143:736–43. [PubMed: 22922517]
90. Baumann AJ, Wheeler DS, James M, Turner R, Siegel A, Navarro VJ. Benefit of Early Palliative Care Intervention in End-Stage Liver Disease Patients Awaiting Liver Transplantation. J Pain Symptom Manage. 2015; 50:882–6. e2. [PubMed: 26303186]
91. Chie WC, Blazey JM, Hsiao CF, et al. International cross-cultural field validation of an European Organization for Research and Treatment of Cancer questionnaire module for patients with primary liver cancer, the European Organization for Research and Treatment of Cancer quality-of-life questionnaire HCC18. Hepatology. 2012; 55:1122–9. [PubMed: 22105642]
92. Gandhi S, Khubchandani S, Iyer R. Quality of life and hepatocellular carcinoma. J Gastrointest Oncol. 2014; 5:296–317. [PubMed: 25083303]
93. Moore GF, Audrey S, Barker M, et al. Process evaluation of complex interventions: Medical Research Council guidance. BMJ (Clinical research ed). 2015; 350:h1258.
94. Temel JS, Greer JA, El-Jawahri A, et al. Effects of Early Integrated Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical Trial. J Clin Oncol. 2017; 35:834–41. [PubMed: 28029308]
95. Murray SA, Kendall M, Boyd K, Sheikh A. Illness trajectories and palliative care. BMJ. 2005; 330:1007–11. [PubMed: 15860828]
96. Gill TM, Gahbauer EA, Han L, Allore HG. Trajectories of disability in the last year of life. The New England journal of medicine. 2010; 362:1173–80. [PubMed: 20357280]
97. Allen LA, Stevenson LW, Grady KL, et al. Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation. 2012; 125:1928–52. [PubMed: 22392529]
### Table 1
Domains of services that can be delivered by an interdisciplinary palliative care team, and examples of specific interventions within each.

| Domain                  | Specific examples                                                                 |
|-------------------------|-----------------------------------------------------------------------------------|
| Symptom management      | Pain, Fatigue, Diarrhea, Skin problems, Anorexia, Weight loss, Obstructive Symptoms, Drowsiness, Dyspnea, Nausea, Depressive symptoms, Anxiety, Encephalopathy |
| Advance care planning   | Elicit decision-making preferences, Identification of healthcare agent, Completion of advance directives (e.g. MOLST/POLST), Discussion of patient’s definition of quality of life |
| Psychosocial support    | Identify religious or spiritual needs, Referral to child-life/art therapy, Referral to support groups |
| Care coordination       | Functional assessment, Coordination of services, Screening for geriatric syndromes (fall risk, polypharmacy, frailty) |
Table 2

Elements of palliative care that may be incorporated into HCC treatment by stage, and elements which might span the course of illness.

| BCLC Stage | A                        | B                                      | C                                         | D                                      |
|------------|--------------------------|----------------------------------------|-------------------------------------------|----------------------------------------|
| Defined by | Disease confined to the liver; eligible for curative therapies | Disease Confined to liver; not eligible for curative therapies | Metastatic disease or portal vein invasion; reduced performance status | Decompensated liver function; reduced performance status |
| Cancer-directed treatments | Resection Liver transplant Ablation | Embolization with intent to control disease or downstage | Chemotherapy/ Immunotherapy | None |
| Potential role of the palliative care interdisciplinary team | Advance care planning discussion prior to surgery | Symptom management; Decisional support around treatment decisions Care coordination | Symptom management Decisional support around treatment decisions | Symptom management End-of-life care preferences Hospice referral |
| | Ongoing discussion of quality-of-life throughout the illness course, which will change over time as HCC progresses; Coping with stigmatization of liver disease/liver cancer; Helping to facilitate illness understanding | | | |